Abstract: A coating composition includes, in relation to 100% of the weight thereof: between 10 and 90 wt. % of at least one film-forming polymer selected from cellulosic polymers or derivatives of cellulosic polymers, derivatives of vinyl alcohol, derivatives of vinyl pyrrolidones, polymers of a natural origin, acrylic or methacrylic derivatives, derivatives of glycol or propylene glycol or combinations of the two substances or the copolymers of vinyl alcohol and polyethylene glycol (PEG); between 1 and 50 wt. % of at least one food colouring agent; and between 0 and 50 wt. % of at least one auxiliary coating agent selected from white opacifiers, diluents, surfactants, plasticizers, and anti-foaming agents.

Abstract: A coating composition includes, in relation to 100% of the weight thereof: between 10 and 90 wt. % of at least one film-forming polymer selected from cellulosic polymers or derivatives of cellulosic polymers, derivatives of vinyl alcohol, derivatives of vinyl pyrrolidones, polymers of a natural origin, acrylic or methacrylic derivatives, derivatives of glycol or propylene glycol or combinations of the two substances or the copolymers of vinyl alcohol and polyethylene glycol (PEG); between 1 and 50 wt. % of at least one food colouring agent; and between 0 and 50 wt. % of at least one auxiliary coating agent selected from white opacifiers, diluents, surfactants, plasticizers, and anti-foaming agents.

Abstract: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.

Abstract: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.

Abstract: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.